Business
Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee Benefit
EsoGuard Testing now incorporated in Texas-based Ancira Auto Group's corporate Health and Wellness Program NEW YORK, Aug. 24, 2023 /PRNewswire/ -- Lucid
About this update from Lucid Diagnostics Inc.
[{"type":"text","content":"EsoGuard Testing now incorporated in Texas-based Ancira Auto Group's corporate Health and Wellness Program\nNEW YORK, Aug. 24, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), announced that the Company has contracted with the Ancira Auto Group (\"Ancira\"), a premier auto dealer serving South Texas, to offer EsoGuard® esophageal precancer testing to eligible employees across all twelve of its locations in San Antonio and surrounding areas. This represents Lucid's first such employer contract as part of a direct contracting strategic initiative it launched earlier this year. Lucid is expanding its commercial team to include a dedicated full-time head of employer relations, who will spearhead this important direct contracting strategic initiative.\n\n \n \n \n \n \n \n\n \n\"Lucid is deeply committed to seeking creative ways to expand patient access to EsoGuard esophageal precancer testing across multiple commercial channels, with the goal of preventing esophageal cancer and cancer deaths,\" said Shaun O'Neil, Lucid's Executive Vice President & Chief Operating Officer. \"We believe we can replicate the success of other early cancer detection companies who have supplemented traditional commercial channels by partnering with employers and other self-insured entities to offer early detection testing as an employee or member benefit. We commend Ancira for their commitment to their employees' long-term health through a robust Health & Wellness Program, and for embracing EsoGuard precancer testing as a cost-effective approach to detect, monitor, and treat a precancer before it develops into a highly lethal cancer. We look forward to offering EsoGuard testing to all at-risk Ancira employees through dedicated on-site #CheckYourFoodTube Precancer Testing events in the coming weeks. We expect this to serve as a model for future contractual engagements with employers, unions, and other self-insured entities, which we believe will supplement the strong commercial progress we are making through more traditional payor pathways.\"\nPursuant to this three-year contract at a negotiated per-employee rate, Lucid will partner with local physicians to identify Ancira employees w...